iBio, Inc.
iBio, Inc. is a U.S.-based preclinical biotechnology company focused on discovering and developing precision antibodies for cardiometabolic and obesity-related diseases. The company uses an AI and machine learning drug discovery platform, and it also develops and licenses early-stage biologic candidates and related intellectual property.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueComputational platform used to identify and optimize novel biologics and precision antibodies.
Early-stage therapeutic candidates such as IBIO-600 and IBIO-610 aimed at cardiometabolic and obesity targets.
Revenue from research services, licenses, and partner collaborations tied to discovery assets.
Owned patents, know-how, and related assets that support development and partnering.
Customers
iBio’s direct customers are typically pharmaceutical and biotechnology partners that license programs, fund collaborations, or receive research services tied to its discovery platform. Its end markets are ultimately patients and physicians in cardiometabolic, obesity, and other therapeutic areas, but near-term monetization depends on partnering with larger drug developers. The company also relies on specialized suppliers and contract service providers to support discovery and preclinical work.
Large or mid-sized drug companies that may license iBio candidates or IP to advance development and commercialization.
Smaller biotech firms or research groups that collaborate on discovery, validation, or target-specific programs.
Counterparties that pay for collaborative research, assay work, or related services tied to platform capabilities.
Patients and clinicians in cardiometabolic and obesity indications who would use approved products if programs succeed.
Strategy
iBio’s strategy is to advance a small number of preclinical antibody programs while using its AI platform to generate differentiated molecules for hard-to-drug targets. It also seeks collaborations and licenses that can monetize discovery assets before internal products reach commercialization. The company’s direction is shaped by the need to convert platform science into partnerable programs and longer-duration therapeutic value.
Pipeline programs are the main source of future value and partnering leverage.
The platform is intended to generate novel biologics that can be licensed or developed.
Partnerships can fund development and create non-dilutive value from early assets.
Geography
iBio is headquartered in the United States and conducts its research and development primarily in San Diego. The company also uses third-party suppliers and collaborators, including international vendors, to support discovery and preclinical work. Its therapeutic programs are described as worldwide in scope, so future partnering and commercialization could extend beyond the U.S.
Risks
iBio faces the typical risks of an early-stage biotech company: clinical and preclinical failure, regulatory uncertainty, and dependence on external capital and partners. Its platform and assets may never produce meaningful revenue, and the company is exposed to supplier concentration, IP impairment risk, and competitive pressure from better-funded drug developers.
- Development-stage program failureImpact: CriticalLikelihood: High
The company is still preclinical, so scientific or translational setbacks could eliminate asset value.
Exposure - Capital access and dilutionImpact: HighLikelihood: High
Long-duration R&D requires external funding before product revenue is available.
Exposure - Competitive and regulatory pressureImpact: HighLikelihood: High
Larger biotech and pharma firms have more resources for R&D, trials, and approvals.
Exposure: AI drug discovery and precision antibody markets
- Partner and collaborator dependenceImpact: HighLikelihood: Medium
Some programs rely on licensees or collaborators to advance development and commercialization.
Exposure: Collaborative research and licensing arrangements
- Supplier and outsourcing concentrationImpact: MediumLikelihood: Medium
Key materials and services are outsourced and may have long lead times or limited alternatives.
Exposure
Accounting
Judgemental itemsIBIO-101 valuation depends on probability-adjusted cash flows and discount rates, which can change materially.
Impact: Could create non-cash impairment charges and affect equity value
Revenue is tied to services and partner arrangements, so timing depends on contract terms and performance obligations.
Impact: Can cause uneven quarterly revenue
Management uses discounted cash flow and weighted-average cost of capital assumptions in valuation work.
Impact: Affects asset carrying values and impairment conclusions
Consultants, outside services, NHP studies, and CMC activities are major cost drivers.
Impact: Influences operating loss and comparability across periods
Similar listed companies
Publicly listed companies with a comparable business focus.
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
IN8bio, Inc
INAB · Biological Products, (No Diagnostic Substances)
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
OmniAb, Inc.
OABIW · Services-Commercial Physical & Biological Research
Veru Inc
VERU · Pharmaceutical Preparations
Last updated: 24/09/2026